- Title
- TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer
- Creators
- Ritu SalaniKristina LindemannL.I.N. ZhongqiuShin NishioAna OakninJ. Emmanuel KurtzGiorgio ValabregaStefania CanovaM. Valeria CáceresPhilipp HarterLucy GilbertAzmat SadozyeJung-Yun LeeToon Van GorpIngrid BoereChristian MarthRadoslaw MadryFlora ZagouriLilian Arruda do Rêgo BarrosLinda DuskaBradley MonkXin Tong LiAgata BoguszSarper TokerMansoor Mirza
- Publication Details
- Gynecologic oncology, Vol.200, pp.121-122
- Identifiers
- 991006226354102656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical cancer
Gynecologic oncology, Vol.200, pp.121-122
09/2025
Metrics
3 Record Views